生物制剂治疗炎症性自身免疫性疾病的皮肤病并发症

JDDG: Journal der Deutschen Dermatologischen Gesellschaft Pub Date : 2019-10-01 DOI:10.1111/ddg.13964

W. Sondermann, Saskia Herz, E. Sody, A. Körber

{"title":"生物制剂治疗炎症性自身免疫性疾病的皮肤病并发症","authors":"W. Sondermann, Saskia Herz, E. Sody, A. Körber","doi":"10.1111/ddg.13964","DOIUrl":null,"url":null,"abstract":"Cutaneous adverse events (CAEs) occur in up to 10 % of patients with immune‐mediated inflammatory disease (IMID) treated with antitumor necrosis factor (TNF)α agents. The aim of this clinical study was to track and observe the course of CAEs in all biologic therapies.","PeriodicalId":14702,"journal":{"name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","volume":"137 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Dermatological complications of therapy with biologics in inflammatory autoimmune diseases\",\"authors\":\"W. Sondermann, Saskia Herz, E. Sody, A. Körber\",\"doi\":\"10.1111/ddg.13964\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cutaneous adverse events (CAEs) occur in up to 10 % of patients with immune‐mediated inflammatory disease (IMID) treated with antitumor necrosis factor (TNF)α agents. The aim of this clinical study was to track and observe the course of CAEs in all biologic therapies.\",\"PeriodicalId\":14702,\"journal\":{\"name\":\"JDDG: Journal der Deutschen Dermatologischen Gesellschaft\",\"volume\":\"137 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JDDG: Journal der Deutschen Dermatologischen Gesellschaft\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/ddg.13964\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ddg.13964","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

摘要

在接受抗肿瘤坏死因子(TNF)α药物治疗的免疫介导性炎症性疾病(IMID)患者中，皮肤不良事件(CAEs)发生率高达10%。本临床研究的目的是跟踪和观察所有生物治疗中CAEs的病程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dermatological complications of therapy with biologics in inflammatory autoimmune diseases

Cutaneous adverse events (CAEs) occur in up to 10 % of patients with immune‐mediated inflammatory disease (IMID) treated with antitumor necrosis factor (TNF)α agents. The aim of this clinical study was to track and observe the course of CAEs in all biologic therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JDDG: Journal der Deutschen Dermatologischen Gesellschaft

自引率

0.00%

发文量